Inflammatory bone loss: pathogenesis and therapeutic intervention

被引:0
作者
Kurt Redlich
Josef S. Smolen
机构
[1] Medical University of Vienna,Division of Rheumatology, Department of Medicine 3
来源
Nature Reviews Drug Discovery | 2012年 / 11卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Bone homeostasis is dependent on the concerted actions of bone-building osteoblasts and bone-degrading osteoclasts — a process called bone remodelling.Two of the major factors that induce osteoblast differentiation and activation are: the signalling mediated by bone morphogenetic proteins via runt-related transcription factor 2; and the WNT–Frizzled–β-catenin pathway. Conversely, Dickkopf-related protein 1 (DKK1) and sclerostin inhibit osteoblast activation.Major molecules involved in osteoclast differentiation and activation include macrophage colony-stimulating factor and receptor activator of nuclear factor-κB (RANK) as well as its ligand (RANKL).Inflammation is associated with the overproduction of various cytokines, such as tumour necrosis factor, interleukin-1 (IL-1), IL-6 or IL-17. Their upregulation in the course of inflammation leads to excessive bone degradation mainly due to hyperactivation of osteoclasts, although some cytokines can also impair osteoblast function.Many diseases lead to inflammatory bone loss, including inflammatory bowel disease, chronic obstructive lung disease, cystic fibrosis, periodontitis, rheumatoid arthritis and other inflammatory diseases.Inflammatory bone loss is always systemic, and in some diseases — such as rheumatoid arthritis or periodontitis — it can also involve local bone.Therapies interfering with inflammation also affect systemic inflammatory bone loss, primarily by reducing the effects of cytokines on osteoclast activation; however, many of these treatments will not fully control inflammation. Owing to this ongoing inflammatory activity (even at low levels), bone loss will continue to accrue and therefore also requires specific targeting of bone cells.Bisphosphonates and denosumab are among the bone-targeting therapies that have been shown to be effective in treating inflammatory bone loss, but it is assumed that blockers of DKK1 and sclerostin — which are upregulated by cytokines and inhibit osteoblast repair mechanisms — are also likely to be effective.
引用
收藏
页码:234 / 250
页数:16
相关论文
共 516 条
[31]  
Kharode YP(2007)Dihydrotestosterone-inducible Dickkopf 1 from balding dermal papilla cells causes apoptosis in follicular keratinocytes Nature Med. 13 156-163
[32]  
Bex FJ(2002)The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma Nature 417 664-667
[33]  
Komm BS(2009)Dickkopf-1 is a master regulator of joint remodeling J. Biol. Chem. 284 10890-10900
[34]  
Gazzerro E(2010)Kremen proteins are Dickkopf receptors that regulate Wnt/β-catenin signalling J. Biol. Chem. 285 14756-14763
[35]  
Canalis E(2002)Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation Cell 108 17-29
[36]  
Franceschi RT(2005)Parathyroid hormone receptor directly interacts with Dishevelled to regulate β-catenin signaling and osteoclastogenesis Nature Med. 11 880-885
[37]  
Xiao G(2009)The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation Nature Med. 15 682-689
[38]  
Zaidi M(2010)NFAT and osterix cooperatively regulate bone formation Nature Rev. Rheumatol. 6 607-611
[39]  
Lian JB(2010)Inhibition of osteoblastic bone formation by nuclear factor-κB Bone 46 1486-1497
[40]  
Yamane T(1998)Novel functions for NFκB: inhibition of bone formation Proc. Natl Acad. Sci. USA 95 3597-3602